Prosecution Insights
Last updated: April 19, 2026

The Firm Of Hueschen And Sage

16 pending office actions • 11 clients

Portfolio Summary

16
Total Pending OAs
5
Final Rejections
11
Non-Final OAs

Client Portfolio (11 clients)

Client (Assignee)Pending OAs
Esteve Pharmaceuticals, S.A. 3
Genetic S.p.A. 2
Novartis AG 2
Italfarmaco Spa 1
Tufts Medical Center, Inc. 1
Oncodesign Precision Medicine (Opm) 1
Sementis Limited 1
Italfarmaco S.p.A. 1
Les Laboratoires Servier 1
Merz Pharma GmbH & Co. Kgaa 1
UNIVERSITA AUTÒNOMA DE BARCELONA 1

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
18426858 MOUNTING PANEL FOR A VERTICAL GARDEN, VERTICAL GARDEN SYSTEM WITH FOLDABLE PANELS, AND MOUNTING AND DISMOUNTING METHODS THEREOF Unknown CALLAWAY, SPENCER THOMAS 3642 Final Rejection Jan 30, 2024
18580322 BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTIASTHMATIC AGENT Genetic S.p.A. SZNAIDMAN, MARCOS L 1628 Non-Final OA Jan 18, 2024
18579645 PROCESS FOR THE PREPARATION OF BUDESONIDE 21-PHOSPHATE Genetic S.p.A. PIHONAK, SARAH 1627 Non-Final OA Jan 16, 2024
18555103 A COMBINATION COMPRISING A SPECIFIC HDAC6 INHIBITOR AND AT LEAST ONE CTLA4 CHECKPOINT INHIBITOR Italfarmaco Spa CHHAY, BONIRATH 1645 Non-Final OA Oct 12, 2023
18554511 TREATMENT OF NEUROPATHIC CORNEAL PAIN WITH NGF Tufts Medical Center, Inc. FISCHER, JOSEPH 1658 Non-Final OA Oct 09, 2023
18551033 NEW PROCESS FOR THE SYNTHESIS OF 5-{5-CHLORO-2-[(3S)-3-[(MORPHOLIN-4-YL)METHYL]-3,4-DIHYDROISOQUINOLINE-2(1H)- CARBONYL]PHENYL}-1,2-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND ITS APPLICATION FOR THE PRODUCTION OF PHARMACEUTICAL COMPOUNDS Novartis AG SEAMAN, D MARGARET M 1625 Non-Final OA Sep 18, 2023
18548231 MACROCYCLIC LRRK2 KINASE INHIBITORS Oncodesign Precision Medicine (Opm) RAO, PADMAJA S 1627 Non-Final OA Aug 29, 2023
18317386 ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 Sementis Limited SALVOZA, M FRANCO G 1672 Final Rejection May 15, 2023
18040708 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS Italfarmaco S.p.A. NOLAN, JASON MICHAEL 1623 Final Rejection Feb 06, 2023
18007321 COMBINATION OF A BCL-2 INHIBITOR AND A HYPOMETHYLATING AGENT FOR TREATING CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF Novartis AG BAUER, NICOLA MARIA 1621 Non-Final OA Jan 30, 2023
18004468 DIOSMIN PREPARATION METHOD Les Laboratoires Servier LEE, HOI YAN NMN 1693 Non-Final OA Jan 06, 2023
17968253 CO-CRYSTALS OF TRAMADOL AND COXIBS Esteve Pharmaceuticals, S.A. LEE, WILLIAM Y 1623 Non-Final OA Oct 18, 2022
17834232 HIGH FREQUENCY APPLICATION OF BOTULINUM TOXIN THERAPY Merz Pharma GmbH & Co. Kgaa HUMPHREY, LOUISE WANG ZHIYING 1657 Final Rejection Jun 07, 2022
17609452 USE OF CO-CRYSTALS OF TRAMADOL AND CELECOXIB FOR TREATING PAIN WHILE REDUCING THE ABUSE LIABILITY OF TRAMADOL Esteve Pharmaceuticals, S.A. MOORE, SUSANNA 1624 Non-Final OA Nov 08, 2021
17413973 RECOMBINANT VECTORS FOR THE LONG TERM TREATMENT OF MUCCHOPOLYSACHARIDOSIS UNIVERSITA AUTÒNOMA DE BARCELONA TRAN, CHRISTINA L 1637 Final Rejection Jun 15, 2021
17336491 COMPOSITIONS COMPRISING TRAMADOL AND CELECOXIB IN THE TREATMENT OF PAIN Esteve Pharmaceuticals, S.A. ORWIG, KEVIN S 3991 Non-Final OA Jun 02, 2021

Managing The Firm Of Hueschen And Sage's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month